Intercept Pharma (ICPT) Tops Q2 EPS by 26c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Intercept Pharmaceuticals (ICPT) PT Raised to $217 at Wedbush
August 6, 2018 7:47 AM EDTWedbush raised its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $217.00 (from $203.00) while maintaining a Outperform rating.
... MoreGoldman Sachs Upgrades Intercept Pharmaceuticals (ICPT) to Buy
August 6, 2018 5:12 AM EDT(Updated - August 6, 2018 7:41 AM EDT)
(updated to correct prior recommendation)
Goldman Sachs upgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Sell to Buy with a price target of $157.00 (from $46.00).
Analyst Salveen Richter says the company's Ocaliva in NASH is the most improtant... More
Intercept Pharmaceuticals (ICPT) PT Raised to $69 at Cantor Fitzgerald
August 3, 2018 7:42 AM EDTCantor Fitzgerald raised its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $69.00 (from $58.00) while maintaining a Neutral rating following the company's 2Q earnings report. For the quarter, ICPT reported net Ocaliva revenues of $43.2 million, slightly above estimates of $42.0 million.
Despite the... More
Intercept Pharmaceuticals (ICPT) PT Raised to $120 at Cowen
August 3, 2018 7:15 AM EDTCowen raised its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $120.00 (from $88.00) while maintaining a Outperform rating.
Analyst Ritu Baral commented, "ICPT 2Q earnings beat revenue expectations: the Ocaliva launch is showing early signs of stabilization and renewed growth. Next... More
Intercept Pharmaceuticals (ICPT) PT Lowered to $115 at RBC Capital
August 2, 2018 12:55 PM EDTRBC Capital lowered its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $115.00 (from $116.00) while maintaining an Outperform rating.
Analyst Brian Abrahams notes Ocaliva PBC revenues slightly beat expectations, with strengthening U.S. and ex-U.S. uptake following the label update. He said... More
